Compare ACRS & METC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACRS | METC |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Coal Mining |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 463.6M |
| IPO Year | 2015 | 2016 |
| Metric | ACRS | METC |
|---|---|---|
| Price | $3.45 | $5.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | $9.82 | ★ $13.73 |
| AVG Volume (30 Days) | ★ 2.6M | 2.0M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 5.00% |
| EPS Growth | ★ 69.01 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | $6.03 |
| Revenue Next Year | N/A | $22.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.46 | $5.73 |
| 52 Week High | $6.60 | $28.67 |
| Indicator | ACRS | METC |
|---|---|---|
| Relative Strength Index (RSI) | 39.18 | 30.66 |
| Support Level | $3.24 | N/A |
| Resistance Level | $4.60 | $7.70 |
| Average True Range (ATR) | 0.28 | 0.64 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 17.03 | 2.70 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Ramaco Resources Inc is a United States-based company that operates as a pure-play metallurgical coal company with operations in southern West Virginia and southwestern Virginia. Its portfolio includes high-quality metallurgical coal reserves & resources, with a focus on properties such as Elk Creek, Berwind, Knox Creek, and Maben. These properties are strategically located to serve North American blast furnace steel mills and coke plants, as well as international metallurgical coal consumers. Additionally, the company controls mineral deposits in Sheridan, Wyoming, exploring potential opportunities in rare earth elements and coal-to-carbon-based products. The company's two operating segments are Metallurgical Coal segment; and Rare Earths and Critical Minerals.